Tiziana's experimental MS treatment meets main goals in mid-stage study

Tiziana Life Sciences

Mon 12:42

Nov 2 (Reuters) - Tiziana Life Sciences TLSA.O said on Monday its experimental therapy for a progressive form of multiple sclerosis with no approved treatments reduced brain inflammation and showed a favorable safety profile in a mid-stage trial.
Shares of the biopharmaceutical company were up more than 7% in premarket trading.

The study met both primary endpoints, with the 50-microgram dose of the nasal treatment significantly reducing brain inflammation versus placebo, while both the 50- and 100-microgram doses met safety goals, Tiziana said
Patients receiving the treatment foralumab showed clinically meaningful reductions in fatigue after 12 weeks, while the placebo group did not, according to the company
Multiple sclerosis is a chronic immune-mediated disease of the brain and spinal cord; Tiziana said its non-active secondary progressive form involves gradually worsening disability without flare-ups or new signs of disease activity
The trial enrolled 48 patients across eight US sites and compared placebo with 50- and 100-microgram doses
No deaths, treatment-related serious side effects or treatment discontinuations were reported during the study, Tiziana said
The most common side effects were headache, falls, nasal congestion and runny nose, according to the company

 (Reporting by Sahil Pandey in Bengaluru; Editing by Vijay Kishore)
 ((Sahil.Pandey@thomsonreuters.com;))